Events in Ukraine appear to be improving, but it may only be a matter of time before they take another turn for the worse. Are you prepared?» Read More
*Apple up after Topsy buy, UBS upgrade. *Yum Brands' November China sales flat. said Gordon Charlop, a managing director at Rosenblatt Securities in New York.
*Apple up after Topsy buy, UBS upgrade. NEW YORK, Dec 3- U.S. stocks were poised for a lower open on Tuesday, indicating the S&P 500 may fall for a third consecutive session, on concerns the Federal Reserve may begin to reduce its stimulus earlier than some had anticipated. said Gordon Charlop, a managing director at Rosenblatt Securities in New York.
Dec 3- Shares of OncoMed Pharmaceuticals Inc soared almost 90 percent in premarket trading after the company said Celgene Corp would help it develop and market six of its experimental anti-cancer stem cell drugs. Celgene will also buy about $22.25 million of OncoMed's common stock for $15.13 per share, giving it a stake of about 5 percent in the company.
Dec 3- OncoMed Pharmaceuticals Inc said Celgene Corp would develop and market six of its anti-cancer stem cell experimental drugs for an upfront payment of $155 million. OncoMed is eligible to receive up to $3 billion in option and milestone payments if Celgene's option to license worldwide rights is exercised and approved, the companies said in a statement.
If you can move somewhat swiftly, Cramer thinks 4 stocks present opportunity right here, right now.
Nov 13- U.S. health regulators on Wednesday approved a drug to treat a rare and aggressive form of non-Hodgkin lymphoma developed by Johnson& Johnson and Pharmacyclics Inc, becoming the second drug that had received the FDA's new breakthrough therapy designation to gain approval.
Nov 13- U.S. health regulators on Wednesday approved a drug to treat a rare and aggressive form of non-Hodgkin lymphoma developed by Johnson& Johnson and Pharmacyclics Inc, marking the second drug that received the FDA's new breakthrough therapy designation to gain approval.
Stocks are at record highs and Wall Street is getting feverishly bullish. What could possibly go wrong?
Oct 24- Celgene Corp raised its earnings forecast for 2013 on Thursday after reporting slightly higher-than-expected quarterly profit on robust sales of its flagship blood cancer drug Revlimid and solid growth in newer cancer treatments.
U.S. stock index futures signaled a higher open on Thursday, with markets still boosted by raised hopes the Federal Reserve will not start tapering off its asset purchases until next year.
Oct 24- Celgene Corp on Thursday reported a slightly higher-than-expected third-quarter profit as sales of its flagship blood cancer drug Revlimid and of Abraxane for breast and lung cancer grew, and the company raised its 2013 earnings forecast.
Oct 24- Celgene Corp on Thursday reported lower third-quarter profit on higher costs, but sales of its flagship blood cancer drug Revlimid and of Abraxane for breast and lung cancer grew and the company raised its 2013 earnings forecast. Excluding special items, Celgene earned $1.56 per share.
With stocks near record highs, strategists are recommending investors focus on stock-picking select names and sectors, rather than the broader market.
Carl Icahn knew not only when to get in but when to get out of Netflix and even had to overrule his own son in making the decision.
Biotech stocks are some of Nasdaq's best performing this year. Joel Sendek, Stifel Nicolaus, looks at names leading the biotech boom.
Sure the shutdown could become frightening. But Cramer doesn’t want it to scare you out of stocks entirely.
Cramer says these 10 stocks are still 'buys' even if the DC debt debacle gets really nasty.
Want to avoid taking a hit on your portfolio because of troubles in Washington? Cramer found one sector that will be a shelter from the storm.
*Shares touch high of $34.19, valuing company at about $900 mln. It also analyzes tissue samples from clinical trials conducted by companies such as Novartis AG, Johnson& Johnson and Celgene Corp. Novartis accounts for more than 10 percent of Foundation Medicine's revenue.
**BLACKBERRY LTD, $10.66, up 3.4 pct. **COTY INC, $15.56, down 4 pct. **ORBITAL SCIENCES CORP, $21.10, up 5 pct.